- ISIN
- IL0011809592
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 9, 2021
Highlights
- EPS (TTM)
- -$0.34
- EBITDA (TTM)
- -$8.55M
- Year Range
- $0.63 - $2.60
- ROA (TTM)
- -842.22%
- ROE (TTM)
- 555.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NRSN Performance Chart
NeuroSense Therapeutics Ltd. (NRSN) is up 1.5% since the beginning of the year. At $1 per share, NRSN is trading 70.0% below its 52-week high of $3.
Loading charts...
Returns By Period
NeuroSense Therapeutics Ltd. (NRSN) has returned 1.48% so far this year and -55.15% over the past 12 months.
NeuroSense Therapeutics Ltd.
- 1D
- -2.45%
- 1M
- -12.31%
- YTD
- 1.48%
- 6M
- -36.55%
- 1Y
- -55.15%
- 3Y*
- -25.40%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
NRSN Monthly Returns History
Based on dividend-adjusted daily data since Dec 9, 2021, NRSN's average daily return is +0.22%, while the average monthly return is +3.08%. At this rate, an investment would double in approximately 1.9 years.
Historically, 44% of months were positive and 56% were negative. The best month was Nov 2023 with a return of +180.1%, while the worst month was Apr 2022 at -57.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, NRSN closed higher 44% of trading days. The best single day was Mar 21, 2022 with a return of +299.4%, while the worst single day was Aug 1, 2025 at -40.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.64% | -1.21% | -16.93% | 8.74% | 0.05% | -4.99% | 1.48% | ||||||
| 2025 | -7.50% | -0.23% | -16.04% | 5.39% | 57.14% | 22.73% | -4.76% | -41.11% | 17.92% | -10.40% | 6.25% | -35.38% | -35.92% |
| 2024 | 59.24% | 41.60% | 2.82% | -25.82% | -20.00% | 3.70% | -32.16% | 17.14% | 42.70% | -1.57% | -21.60% | 22.45% | 52.87% |
| 2023 | 27.05% | 20.00% | -7.53% | 17.44% | -22.77% | -4.49% | -12.75% | -27.69% | -24.47% | -35.13% | 180.07% | -39.15% | -35.66% |
| 2022 | -19.92% | 31.98% | 52.69% | -57.68% | -16.07% | 139.72% | -44.67% | 4.28% | -8.21% | -10.61% | 7.50% | -29.07% | -50.41% |
| 2021 | -39.11% | -39.11% |
Benchmark Metrics
NeuroSense Therapeutics Ltd. has an annualized alpha of 61.23%, beta of 0.60, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 10, 2021.
- This stock participated in 188.67% of S&P 500 Index downside but only 29.91% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.60 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 61.23%
- Beta
- 0.60
- R²
- 0.00
- Upside Capture
- 29.91%
- Downside Capture
- 188.67%
Return for Risk
Risk / Return Rank
NRSN ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NeuroSense Therapeutics Ltd. (NRSN) and compare them to S&P 500 Index.
| NRSN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.84 | ||
| Sortino ratioReturn per unit of downside risk | -3.60 | ||
| Omega ratioGain probability vs. loss probability | 0.93 | 1.41 | -0.47 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 2.93 | -3.69 |
| Martin ratioReturn relative to average drawdown | -0.98 | 13.52 | -14.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeuroSense Therapeutics Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeuroSense Therapeutics Ltd. was 92.90%, occurring on Oct 30, 2023. The portfolio has not yet recovered.
The current NeuroSense Therapeutics Ltd. drawdown is 87.47%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -92.90%Oct 2023 | 1y 7mo | — | 4y 2moMar 2022 - now |
Bear market2022 | -67.08%Mar 2022 | 3mo 4d | 7d | 3mo 11dDec 2021 - Mar 2022 |
Drawdown Indicators
| NRSN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.90% | -56.78% | -36.12% |
Max Drawdown (1Y)Largest decline over 1 year | -72.29% | -9.10% | -63.19% |
Max Drawdown (3Y)Largest decline over 3 years | -79.03% | -18.90% | -60.13% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.47% | -0.74% | -86.73% |
Average DrawdownAverage peak-to-trough decline | -76.50% | -10.72% | -65.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 56.27% | 1.97% | +54.30% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeuroSense Therapeutics Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeuroSense Therapeutics Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NRSN
Add NeuroSense Therapeutics Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NRSN